Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1000 participants
OBSERVATIONAL
2019-11-17
2025-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Surprisingly little is known about the determinants and consequences of this variation. The investigators will study the following milk components in the IMiC Consortium to understand variability between individual women and across different geographic settings, and their associations with infant growth. In addition, to guide these analyses, a review of human milk components and infant growth will be undertaken by the IMiC members during Year 1 of the Project.
Priority Components (to be analyzed in all samples):
Macronutrients include carbohydrates (primarily lactose), proteins and lipids. Lipids provide about 50% of the energy content in human milk. The vast majority (98%) of milk lipids are triacylglycerides, with the remainder consisting of diacylglycerides, monoacylglycerides, free fatty acids, phospholipids and cholesterol. The fatty acid profile of human milk varies in relation to maternal diet and genetics, particularly in the long-chain polyunsaturated fatty acids (LCPUFAs), such as arachidonic and docosahexaenoic acids, which contribute to immune function and neurodevelopment.
Micronutrient quality and concentrations can be compromised by maternal malnutrition. Micronutrients in milk include minerals (e.g. Zinc, Calcium, Phosphorus, Magnesium, Iodine, Selenium) and vitamins (A, B1, B2, B6, B12, C, D, E; folate, choline).
Immunoglobulins (Ig) are transferred in human milk, including IgA, IgM and IgG. Infants are born with immature adaptive immunity, and rely on these maternal antibodies for defense against pathogens. Soluble IgA (sIgA) is the predominant antibody of human milk; sIgA-antigen complexes are taken up by intestinal dendritic cells, allowing for antigen recognition.
Cytokines are multifunctional peptides can cross the intestinal barrier, where they influence immune activity. Milk-borne cytokines include anti-inflammatory transforming growth factor (TGF)-b, interleukins (IL)-10 and IL-7, and proinflammatory tumor necrosis factor (TNF)-a, IL-6, IL-8, and interferon (IFN)-g.
Lactoferrin is an iron binding glycoprotein with antimicrobial activity against many bacteria, viruses, and fungi. Osteopontin is an extensively phosphorylated acidic glycoprotein that is present at high concentrations in human milk. It affects immune functions, intestinal development, and brain development.
Growth factors and hormones in human milk have wide-ranging effects on the infant intestinal tract, vasculature, nervous system, and endocrine system. Some act locally on the neonatal intestine and many are absorbed into systemic circulation through the 'leaky' infant gut. Epidermal growth factor (EGF) is critical to the maturation and healing of the intestinal mucosa. Insulin-like growth factor (IGF) promotes tissue growth. The metabolic hormones leptin, insulin, adiponectin and ghrelin regulate energy conservation, appetite and infant BMI.
Human milk oligosaccharides (HMOs) are the third most abundant component of human milk. Over 100 different HMOs have been identified. These structurally diverse carbohydrates are not digested by the infant, but are metabolized by the infant's gut bacteria, providing a selective substrate to help shape the developing microbiome. In addition, HMOs serve as soluble decoy receptors and prevent pathogen attachment to infant mucosal surfaces, lowering the risk for viral and bacterial infections. HMOs may also modulate epithelial and immune cell responses and provide the infant with sialic acid, an important nutrient for brain development. In the CHILD cohort the investigators have observed that, beyond genetic secretor status, HMO composition is associated with ethnicity, lactation stage, parity, geographic location, season of collection, and breastfeeding exclusivity.
Omics approaches will be applied to broadly assess the complete spectrum of peptides, proteins, lipids, and metabolites in human milk. Targeted metabolomics analyses to be conducted using the Biocrates platform (\~500 metabolites), untargeted metabolomic analyses to be conducted by Sapient Bioanalytics via mass spectrometry.
Microbes are present in human milk. Culture-dependent and independent (sequencing-based) studies have confirmed the presence of bacteria and fungi in milk from healthy mothers. In the CHILD cohort, the investigators have found that milk microbiota composition differs by infant sex, method of feeding, maternal BMI, and maternal atopy. It is estimated that breastfed infants receive 10\^4-10\^6 bacteria per day, providing a source of live microbes to seed the infant gut, oral cavity and airways. Studies demonstrating strain similarities between maternal gut, milk, and infant gut support this hypothesis, and find that Bifidobacterium spp. constitute the majority of shared taxa between maternal milk and infant stool. Given the central role of the gut microbiome in infant growth, metabolism and protection from infectious disease, including in low to middle income (LMIC) settings, it is critical to understand the origins of these fundamentally important gut microbes early in life.
A secondary objective of IMiC will be to support data integration across sites to answer important questions related to 1) the impact of maternal health and nutrition interventions on breast milk composition, and 2) its relation to infant health, growth and development. Each site will own its own data and will also be independently addressing these same questions by site, as originally intended in their own grants/studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Canadian Healthy Infant Longitudinal Development (CHILD) Cohort Study
The CHILD Cohort Study is a prospective longitudinal birth cohort study. It is an observational study of healthy term infants in Canada (Vancouver, Edmonton, Manitoba, Toronto). The birth years were between 2009-2012, and is currently at the 8 year postnatal follow up phase. IMiC will receive 400 breast milk samples from 400 dyads (100/site) that were taken between 3-4 months postnatal.
No interventions assigned to this group
The Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT) Study
(NCT03268902). ELICIT is a randomized controlled trial (RCT) evaluating the efficacy of antimicrobials and nicotinamide in increasing growth in the setting of Rural Tanzania. It is factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis to infants. IMiC will receive 400 breast milk samples from 200 dyads, 2 samples per dyad taken at 1 \& 5 months postnatal.
Vitamin B3
ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
Azithromycin
ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.
VITAL Pakistan
Two Randomized Controlled Trials: Mumta (Nutritional support for lactating women with or without azithromycin)PW - NCT04012177 and MumtaLW - NCT03564652 VITAL is a community-based, randomized control, assessor blinded trial in peri-urban settings of Karachi, Pakistan to study the impact of Lipid-based Nutritional Supplement for Pregnant and Lactating women which is balanced energy-protein (BEP) dietary supplement, a locally produced ready-to-use nutritional product for lactating women (LW) and single prophylaxis dose of Azithromycin for infants, on growth of infants over the period of six months since birth compared to current standard of care. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 \& 2-3 months.
Azithromycin
ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.
Fortified food supplement
VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.
MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label).
Micronutriments pour la Santé de la Mère et de l'Enfant (MISAME)-3 study (NCT03533712)
MISAME-3 is a randomized controlled clinical trial in the setting of Rural Burkina Faso. A BEP supplement provides less than 25% of protein of the total energy content, and includes different vitamins and minerals. The first part of an exploratory study will determine which type of BEP supplement (bar, drink, biscuit, soup or paste) is most accepted by pregnant women. Subsequently, two products will be tested for longer-term acceptability and at-home use (phase 1). The effect of the most suitable supplement will be tested in a controlled clinical trial (phase 2). The intervention group will receive the dietary supplement during pregnancy and/or lactation, while the control group complies with the standard iron and folic acid tablets following the national guidelines. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 \& 3-4 months.
Fortified food supplement
VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.
MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin B3
ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
Azithromycin
ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.
Fortified food supplement
VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.
MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ELICIT Study: Adult mothers, child \<14 days, lives within 25km of Haydom
* VITAL Study: Lactating, biological mothers
* MISAMEIII Study: Confirmed (pregnancy test/ultrasound) pregnant women 15-40 years old, informed consent, self, parents or husband (for minors; assent).
Exclusion Criteria
* ELICIT Study: Multiple gestation, birth defects/neonatal illness, weight \<1.5g, no intention to breastfeed, will move from area within 18 months
* VITAL Study: Use of any ointments or topical solutions immediately prior to sampling, non-consent
* MISAMEIII Study: Peanut allergy, gestational age \<20weeks, women who will not deliver babies in or live in study area by delivery date.
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bill and Melinda Gates Foundation
OTHER
Stanford University
OTHER
The University of Western Australia
OTHER
University of Idaho
OTHER
Ludwig-Maximilians - University of Munich
OTHER
Johns Hopkins University
OTHER
Cedars-Sinai Medical Center
OTHER
Sapient Bioanalytics
UNKNOWN
University of California, Davis
OTHER
University of California, San Diego
OTHER
University of Virginia
OTHER
Aga Khan University
OTHER
University Ghent
OTHER
University of California, Berkeley
OTHER
University Health Network, Toronto
OTHER
USDA Beltsville Human Nutrition Research Center
FED
Antigen Discovery Inc
UNKNOWN
USDA, Western Human Nutrition Research Center
FED
University of Manitoba
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Meghan B Azad
Role: PRINCIPAL_INVESTIGATOR
University of Manitoba, CHILD Cohort Study
Estomih Mduma
Role: STUDY_DIRECTOR
Haydom Lutheran Hospital, ELICIT Trial
Fyezah Jehan
Role: PRINCIPAL_INVESTIGATOR
Aga Khan University Pakistan, VITAL Trial
Laeticia Celine Toe
Role: STUDY_DIRECTOR
Institut de Recherche en Science de la Santa, MISAMEIII Trial
PJ Subbarao
Role: STUDY_DIRECTOR
SickKids, CHILD Study
Yasir Shafiq
Role: PRINCIPAL_INVESTIGATOR
Aga Khan University Pakistan, VITAL Trial
Mark D DeBoer
Role: PRINCIPAL_INVESTIGATOR
University of Virginia, VITAL Trial
Patrick Kolsteren
Role: PRINCIPAL_INVESTIGATOR
Ghent University, MISAMEIII Trial
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Manitoba Interdisciplinary Lactation Centre (MILC)
Winnipeg, Manitoba, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Andreas NJ, Kampmann B, Mehring Le-Doare K. Human breast milk: A review on its composition and bioactivity. Early Hum Dev. 2015 Nov;91(11):629-35. doi: 10.1016/j.earlhumdev.2015.08.013. Epub 2015 Sep 12.
Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. Pediatr Clin North Am. 2013 Feb;60(1):49-74. doi: 10.1016/j.pcl.2012.10.002.
Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012 Sep;22(9):1147-62. doi: 10.1093/glycob/cws074. Epub 2012 Apr 18.
Azad MB, Robertson B, Atakora F, Becker AB, Subbarao P, Moraes TJ, Mandhane PJ, Turvey SE, Lefebvre DL, Sears MR, Bode L. Human Milk Oligosaccharide Concentrations Are Associated with Multiple Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices. J Nutr. 2018 Nov 1;148(11):1733-1742. doi: 10.1093/jn/nxy175.
Innis SM. Impact of maternal diet on human milk composition and neurological development of infants. Am J Clin Nutr. 2014 Mar;99(3):734S-41S. doi: 10.3945/ajcn.113.072595. Epub 2014 Feb 5.
Dror DK, Allen LH. Overview of Nutrients in Human Milk. Adv Nutr. 2018 May 1;9(suppl_1):278S-294S. doi: 10.1093/advances/nmy022.
Dawod B, Marshall JS. Cytokines and Soluble Receptors in Breast Milk as Enhancers of Oral Tolerance Development. Front Immunol. 2019 Jan 22;10:16. doi: 10.3389/fimmu.2019.00016. eCollection 2019.
Garofalo R. Cytokines in human milk. J Pediatr. 2010 Feb;156(2 Suppl):S36-40. doi: 10.1016/j.jpeds.2009.11.019.
Demmelmair H, Prell C, Timby N, Lonnerdal B. Benefits of Lactoferrin, Osteopontin and Milk Fat Globule Membranes for Infants. Nutrients. 2017 Jul 28;9(8):817. doi: 10.3390/nu9080817.
Jiang R, Lonnerdal B. Biological roles of milk osteopontin. Curr Opin Clin Nutr Metab Care. 2016 May;19(3):214-9.
Chan D, Goruk S, Becker AB, Subbarao P, Mandhane PJ, Turvey SE, Lefebvre D, Sears MR, Field CJ, Azad MB. Adiponectin, leptin and insulin in breast milk: associations with maternal characteristics and infant body composition in the first year of life. Int J Obes (Lond). 2018 Jan;42(1):36-43. doi: 10.1038/ijo.2017.189. Epub 2017 Aug 14.
Young BE, Patinkin Z, Palmer C, de la Houssaye B, Barbour LA, Hernandez T, Friedman JE, Krebs NF. Human milk insulin is related to maternal plasma insulin and BMI: but other components of human milk do not differ by BMI. Eur J Clin Nutr. 2017 Sep;71(9):1094-1100. doi: 10.1038/ejcn.2017.75. Epub 2017 May 17.
Moossavi S, Miliku K, Sepehri S, Khafipour E, Azad MB. The Prebiotic and Probiotic Properties of Human Milk: Implications for Infant Immune Development and Pediatric Asthma. Front Pediatr. 2018 Jul 24;6:197. doi: 10.3389/fped.2018.00197. eCollection 2018.
Musilova S, Rada V, Vlkova E, Bunesova V. Beneficial effects of human milk oligosaccharides on gut microbiota. Benef Microbes. 2014 Sep;5(3):273-83. doi: 10.3920/BM2013.0080.
Wang B. Molecular mechanism underlying sialic acid as an essential nutrient for brain development and cognition. Adv Nutr. 2012 May 1;3(3):465S-72S. doi: 10.3945/an.112.001875.
McGuire MK, McGuire MA. Got bacteria? The astounding, yet not-so-surprising, microbiome of human milk. Curr Opin Biotechnol. 2017 Apr;44:63-68. doi: 10.1016/j.copbio.2016.11.013. Epub 2016 Dec 8.
Ruiz L, Garcia-Carral C, Rodriguez JM. Unfolding the Human Milk Microbiome Landscape in the Omics Era. Front Microbiol. 2019 Jun 25;10:1378. doi: 10.3389/fmicb.2019.01378. eCollection 2019.
Togo A, Dufour JC, Lagier JC, Dubourg G, Raoult D, Million M. Repertoire of human breast and milk microbiota: a systematic review. Future Microbiol. 2019 May;14:623-641. doi: 10.2217/fmb-2018-0317. Epub 2019 Apr 26.
Moossavi S, Sepehri S, Robertson B, Bode L, Goruk S, Field CJ, Lix LM, de Souza RJ, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Moraes TJ, Lefebvre DL, Sears MR, Khafipour E, Azad MB. Composition and Variation of the Human Milk Microbiota Are Influenced by Maternal and Early-Life Factors. Cell Host Microbe. 2019 Feb 13;25(2):324-335.e4. doi: 10.1016/j.chom.2019.01.011.
Asnicar F, Manara S, Zolfo M, Truong DT, Scholz M, Armanini F, Ferretti P, Gorfer V, Pedrotti A, Tett A, Segata N. Studying Vertical Microbiome Transmission from Mothers to Infants by Strain-Level Metagenomic Profiling. mSystems. 2017 Jan 17;2(1):e00164-16. doi: 10.1128/mSystems.00164-16. eCollection 2017 Jan-Feb.
Biagi E, Quercia S, Aceti A, Beghetti I, Rampelli S, Turroni S, Faldella G, Candela M, Brigidi P, Corvaglia L. The Bacterial Ecosystem of Mother's Milk and Infant's Mouth and Gut. Front Microbiol. 2017 Jun 30;8:1214. doi: 10.3389/fmicb.2017.01214. eCollection 2017.
Blanton LV, Barratt MJ, Charbonneau MR, Ahmed T, Gordon JI. Childhood undernutrition, the gut microbiota, and microbiota-directed therapeutics. Science. 2016 Jun 24;352(6293):1533. doi: 10.1126/science.aad9359.
Gehrig JL, Venkatesh S, Chang HW, Hibberd MC, Kung VL, Cheng J, Chen RY, Subramanian S, Cowardin CA, Meier MF, O'Donnell D, Talcott M, Spears LD, Semenkovich CF, Henrissat B, Giannone RJ, Hettich RL, Ilkayeva O, Muehlbauer M, Newgard CB, Sawyer C, Head RD, Rodionov DA, Arzamasov AA, Leyn SA, Osterman AL, Hossain MI, Islam M, Choudhury N, Sarker SA, Huq S, Mahmud I, Mostafa I, Mahfuz M, Barratt MJ, Ahmed T, Gordon JI. Effects of microbiota-directed foods in gnotobiotic animals and undernourished children. Science. 2019 Jul 12;365(6449):eaau4732. doi: 10.1126/science.aau4732.
Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, Benezra A, DeStefano J, Meier MF, Muegge BD, Barratt MJ, VanArendonk LG, Zhang Q, Province MA, Petri WA Jr, Ahmed T, Gordon JI. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature. 2014 Jun 19;510(7505):417-21. doi: 10.1038/nature13421. Epub 2014 Jun 4.
Foroutan A, Guo AC, Vazquez-Fresno R, Lipfert M, Zhang L, Zheng J, Badran H, Budinski Z, Mandal R, Ametaj BN, Wishart DS. Chemical Composition of Commercial Cow's Milk. J Agric Food Chem. 2019 May 1;67(17):4897-4914. doi: 10.1021/acs.jafc.9b00204. Epub 2019 Apr 17.
Fehr K, Mertens A, Shu CH, Dailey-Chwalibog T, Shenhav L, Allen LH, Beggs MR, Bode L, Chooniedass R, DeBoer MD, Deng L, Espinosa C, Hampel D, Jahual A, Jehan F, Jain M, Kolsteren P, Kawle P, Lagerborg KA, Manus MB, Mataraso S, McDermid JM, Muhammad A, Peymani P, Pham M, Shahab-Ferdows S, Shafiq Y, Subramoney V, Sunko D, Toe LC, Turvey SE, Xue L, Rodriguez N, Hubbard A, Aghaeepour N, Azad MB. Protocol: the International Milk Composition (IMiC) Consortium - a harmonized secondary analysis of human milk from four studies. Front Nutr. 2025 Jun 10;12:1548739. doi: 10.3389/fnut.2025.1548739. eCollection 2025.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H2020:161
Identifier Type: OTHER
Identifier Source: secondary_id
HS23767
Identifier Type: -
Identifier Source: org_study_id